Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

SC Fundamental Value Fund Send Letter to Transcept Pharmaceuticals Inc (TSPT); Request Special Shareholder Meeting

SC Fundamental Value Fund, L.P. is unhappy with the management of Transcept Pharmaceuticals Inc (NASDAQ:TSPT). In a recent filing with the Securities and Exchange Commission, the fund has reiterated its stake in Transcept Pharmaceuticals. SC Fundamental Value Fund holds 1.2 million shares which account for 6.7% of the company’s common stock. Also mentioned in the filing is that the management of the fund has sent a letter via Email to the company’s board of directors to request a special shareholder meeting.

Transcept Pharmaceuticals

According to the excerpts of the Email attached to the filing, SC Fundamental Value Fund is dissatisfied with the fact that the management of Transcept Pharmaceuticals Inc (NASDAQ:TSPT) is considering distributing a share of its cash to its holders, with the rest being invested in the operations of a private company. This new direction of development contradicts the company’s previous resolution to either sell itself or initiate liquidation by the end of March 2014. The management of SC Fundamental Value Fund argues that the decision to either roll the dice one more time or be sold or liquidated should be taken by the shareholder and thus requests a special meeting for December 19th, 2013.

Transcept Pharmaceuticals Inc (NASDAQ:TSPT) engages in the development of  therapeutic products used in the field of neuroscience. So far this year the stock has fallen 19.5% to a price of $3.62 per share and is trading close to the all time low of $2.52. The company has a market cap of $68.2 million and a beta of 1.59, which makes it a fairly volatile stock. Transcept Pharmaceuticals does not pay a dividend. For the third quarter of 2013, the company posted net revenues of $382,000 and a loss per share of $0.25. According to the same financial report, at the end of September 2013, the company had $79.3 million in assets and debts of approximately $3 million. Thus, net tangible assets amount to about $76 million, more than the market cap of the company.

Disclosure: none

Recommended reading:

Cannell Capital Raises Holding in Hooper Holmes, Inc. (HH) Even Higher

Nelson Peltz, Trian Partners Reveal New Position in Ingersoll-Rand PLC (IR)’s Spin-Off Allegion PLC (ALLE)

Mario Gabelli Increases Holding in Layne Christensen Company (LAYN)

Loading...